![Christopher Benecchi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Benecchi
Corporate Officer/Principal bei SAGE THERAPEUTICS, INC.
Vermögen: 65 882 $ am 31.05.2024
Profil
Christopher Benecchi is currently the Chief Business Officer at SAGE Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021.
Before that, he was the Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2011 to 2019.
Mr. Benecchi holds an MBA from Duke University and completed his undergraduate studies at Colby College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0,01% | 31.03.2024 | 5 930 ( 0,01% ) | 65 882 $ | 31.05.2024 |
Aktive Positionen von Christopher Benecchi
Unternehmen | Position | Beginn |
---|---|---|
SAGE THERAPEUTICS, INC. | Corporate Officer/Principal | 21.09.2021 |
Ehemalige bekannte Positionen von Christopher Benecchi
Unternehmen | Position | Ende |
---|---|---|
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.09.2021 |
UCB, Inc.
![]() UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01.08.2019 |
Ausbildung von Christopher Benecchi
Duke University | Masters Business Admin |
Colby College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SAGE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UCB, Inc.
![]() UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |